sulfo-spdb

sulfo-SPDB is a cleavable linker vital in ADC synthesis. sulfo-SPDB joins cytotoxic drugs to antibodies, enabling precise delivery to cells or proteins. The cleavable nature ensures controlled drug release, optimizing ADC effectiveness.

Sulfo-SPDB-DM4 is a drug-linker conjugate designed for antibody-drug conjugates (ADCs) that employs the maytansine-based payload (DM4, an antitubulin agent) connected through the sulfo-SPDB linker.

Sulfo-SPDB-DGN462为一种ADC活性连接剂，毒素DGN462通过可裂解的Sulfo-SPDB linker偶联形成。DGN462是一种DNA烷基化剂，对抗肿瘤（如急性髓系白血病[AML]）表现出有效性。

SPDB-sulfo, a glutathione-cleavable linker, is utilized in the development of antibody-drug conjugates (ADCs) [1].

NO2-SPDB-sulfo is a cleavable linker vital in ADC synthesis. NO2-SPDB-sulfo joins cytotoxic drugs to antibodies, enabling precise delivery to cells or proteins. The cleavable nature ensures controlled drug release, optimizing ADC effectiveness.

DMAC-SPDB-sulfo is a cleavable linker vital in ADC synthesis. DMAC-SPDB-sulfo joins cytotoxic drugs to antibodies, enabling precise delivery to cells or proteins. The cleavable nature ensures controlled drug release, optimizing ADC effectiveness.

Anti-CCL2 (Carlumab)-SPDB-DM4 是一种抗体-药物偶联物 (ADC)，由人源性抗CCL2 (趋化因子配体 2) 抗体 Carlumab 通过连接子 SPDB 和微管蛋白 (tubulin) 抑制剂 DM4 连接而成。其毒性分子和连接体部分为 sulfo-SPDB-DM4，可用于癌症研究。

Anti-SLC34A2 (Lifastuzumab)-SPDB-DM4 是一种抗体-药物偶联物 (ADC)，由人源抗SLC34A2(钠依赖性磷酸转运蛋白 2) 的抗体 Lifastuzumab 与连接子 SPDB 以及微管蛋白 (tubulin) 抑制剂 DM4 结合而成。其 ADC 的毒性分子和连接子部分为 sulfo-SPDB-DM4。Anti-SLC34A2 (Lifastuzumab)-SPDB-DM4 适用于癌症研究。